Therapy News and Research

RSS

Patient self-referral to physiotherapy proven to be safe, and results in better health outcomes

Today in Washington, DC, physiotherapists from around the world heard that direct patient access and self-referral to physiotherapy improves public health. Patient self-referral and direct access is proven to be safe, and results in better health outcomes, more timely care, higher patient satisfaction, and lower costs.

28 Oct 2009

Catheter-directed therapy safe and effective for treating acute pulmonary embolism

William Kuo, MD, was the on-call interventional radiologist one Friday night three years ago when he received a call from the intensive care unit at Stanford Hospital & Clinics. He was asked to attend to a 62-year-old woman who had collapsed at home and was rushed to the emergency room with massive blood clots in her lungs.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Two-year trial to test effectiveness of behavioral psychotherapy for young adolescents with autism

The USF Health Rothman Center for Neuropsychiatry in St. Petersburg, FL, is conducting a two-year federal trial testing the effectiveness of behavioral psychotherapy in treating anxiety among young adolescents with autism.

28 Oct 2009

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate, a beta-blocker medication taken by over half a million Americans for the treatment of high blood pressure, TOPROL-XL and its authorized generic, metoprolol succinate extended-release tablets are available.

28 Oct 2009

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

28 Oct 2009

Development of VLN cigarettes for use in smoking cessation continues: 22nd Century

22nd Century Limited, LLC is pleased to announce that it is continuing development of a very low nicotine cigarette for use in smoking cessation. Clinical trial results demonstrate that these cigarettes, also referred to as ‘nicotine-free’ and ‘denicotinized,’ may be more effective for quitting than FDA-approved therapies.

28 Oct 2009

IPIT uses Affymetrix’s DMET Plus biomarker panel to expand the PGENI

Affymetrix, Inc. announced today that the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina in Chapel Hill is using the company’s DMET™ Plus biomarker panel to expand the Pharmacogenetics for Every Nation Initiative (PGENI).

28 Oct 2009

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived. Immature eggs are normally discarded during standard in vitro fertilization (IVF) procedures due to their inability to create an embryo.

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

28 Oct 2009

Medtronic reports outcome of its Transcatheter Pulmonary Valve trial

Clinical trial results published in this week’s Journal of the American College of Cardiology (JACC) describe six-month outcomes for patients using the Melody® Transcatheter Pulmonary Valve from Medtronic, Inc.. The valve is implanted through a catheter procedure instead of open-heart surgery in patients with congenital heart disease affecting the function of their pulmonary valve.

28 Oct 2009

EnteroMedics to reduce its workforce and operating costs

EnteroMedics Inc., today announced that it has implemented a plan to reduce its workforce and operating costs in order to preserve capital and streamline its operations following the announcement of top-line results from its pivotal EMPOWER study on October 2, 2009. The reduction in force will lower the number of employees by 40%, to a total of 33, by November 15, 2009.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Contour Products promotes the results of a 2009 survey conducted among respiratory therapists

In conjunction with National Respiratory Care Week, Contour Products(TM), a leader in the sleep support and comfort industry, is proud to promote the results of a 2009 survey conducted among respiratory therapists who work with CPAP patients daily. One of the most common issues among CPAP therapy users is discomfort when sleeping with their CPAP mask, as a result of the mask pressing against their face.

28 Oct 2009

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

POZEN announces Phase I study results of PA65020

POZEN Inc. announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

28 Oct 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

Therapy News and Research

Patient self-referral to physiotherapy proven to be safe, and results in better health outcomes

Catheter-directed therapy safe and effective for treating acute pulmonary embolism

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Two-year trial to test effectiveness of behavioral psychotherapy for young adolescents with autism

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

Development of VLN cigarettes for use in smoking cessation continues: 22nd Century

IPIT uses Affymetrix’s DMET Plus biomarker panel to expand the PGENI

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Medtronic reports outcome of its Transcatheter Pulmonary Valve trial

EnteroMedics to reduce its workforce and operating costs

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Contour Products promotes the results of a 2009 survey conducted among respiratory therapists

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

Recruitment of Phase II trial of TB-402 completed ahead of schedule

POZEN announces Phase I study results of PA65020

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News